1.The Cultivation of Harmonious Employment Ethics of Medical Students
Chinese Medical Ethics 1996;0(01):-
Combining with the disharmonious ethical phenomena in employment of medical students at present,this paper analyses its subjective and objective reasons,and puts forward some practical approaches to the cultivation of harmonious employment ethics of medical students.
2.Setting up the Ideology of Humanism to do Better Employment of Medical Graduate
Qingzhong PAN ; Aiqin ZHANG ; Ruirong WEI
Chinese Medical Ethics 1996;0(01):-
Combing with the ideology of humanism to expound the intention of the ideology of humanism in the employment work of graduate. Advancing the thinking and practice to carry out the ideology of humanism in the employment work of graduate.
3.Progress on diagnosis and treatment of histiocytic cell sarcoma
Guozheng PAN ; Jiaobang XU ; Qingzhong YUAN
Chinese Journal of Clinical Oncology 2016;43(5):220-222
Histiocytic sarcoma is a rare kind of histiocytic lymphoma with an undetectable onset, no specific clinical and imaging mani-festations, and rapid progression. At diagnosis, the histiocytic sarcoma has already spread significantly in most patients. The diagnosis of histiocytic sarcoma depends on the basis of its mitotic figures and at least expression of one of the following:CD68, CD163, and lyso-zyme. Operation excision, radiotherapy, and chemotherapy are currently the more common treatment methods for histiocytic sarco-ma. However, no unified curative and treatment standard exists, and prognosis is poor. This review summarizes the diagnosis and treat-ment of histiocytic sarcoma.
4.Effect of CIK on long-term survival and hepatitis B reactivation in the treatment of hepatocellular carcinoma after RFA and TACE
Jiaobang XU ; Guozheng PAN ; Jian ZHANG ; Long HAO ; Shilei LI ; Qingzhong YUAN
Chinese Journal of General Surgery 2016;31(10):854-858
Objective To evaluate effects of autologous cytokine-induced killer cell (CIK) transfusion on the survival and hepatitics B virus (HBV) reactivation after radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE).Methods A retrospective analysis was conducted on 185 patients with hepatocellular carcinoma treated from Mar 2007 to Oct 2013.Patients were divided into study group (RFA,TACE,CIK) of 98 cases and control group (RFA,TACE) of 87 cases.According to tumor size,numbers and vascular invasion,patients were stratified into 4 subgroups:the high and the low risk group respectively with tumor ≤ 5 cm and > 5 cm.Results The 1-,3-,5-year survival rate between study and control group were not significantly different:75.5% (74/98),57.1% (56/98),20.4% (20/98) vs.71.2% (62/87),54.0% (47/87),21.8% (19/87) (P > 0.05).Only the study group's 1-,3-,5-year survival rate of high risk patients with tumor ≤ 5 cm were higher than the control group:75.0% (21/28),53.6% (15/28),35.7 % (10/28) vs.61.9% (13/21),42.9% (9/21),23.5% (5/21) (P < 0.05).The incidence of HBV reactivation was lower in dunantiviral patients who received CIK therapy than those who had 6.0% (3/50) vs.23.5% (12/61) (P < 0.05).Conclusion Postoperative adjuvant CIK therapy with tumor≤5cm after RFA combined with TACE was beneficial to the survival of high risk patients and decreased the risk of HBV reactivation.
5.The impact of hepatectomy combined with splenectomy on perioperative hepatitis B virus reactivation in patients with hepatocellular carcinoma ≤ 5 cm and hypersplenism
Jiaobang XU ; Shilei LI ; Jian ZHANG ; Faping YOU ; Guozheng PAN ; Qingzhong YUAN ; Rui ZHU
Chinese Journal of Hepatobiliary Surgery 2017;23(7):448-451
Objective To investigate the impact of hepatectomy combined with splenectomy on hepatitis B virus (HBV) reactivation in patients with hepatocellular carcinoma (HCC) ≤5 cm and with hypersplenism.Methods This is a retrospective case-control study on 167 patients with HCC ≤5 cm and with hypersplenism who underwent hepatectomy combined with splenectomy at the Shengli Oilfield Central Hospital between May 2008 and June 2015.64 patients underwent hepatectomy combined with splenectomy,and 103 patients hepatectomy alone.The patients were assigned to the hepatectomy combined with splenectomy group (the combined group,n =61) or the hepatectomy alone group (the control group,n =61) using propensity score matching (PSM).Logistic regression was used to evaluate the relative clinical factors associated with HBV reactivation.The stratified Chi-squared test was utilized to determine the impact of the surgical procedure and preoperative anti-viral therapy on postoperative hepatitis B virus reactivation of these patients.Results The serum PLT level,Child-Pugh grading,tumor diameter and surgical procedures were shown to be independent risk factors associated with postoperative HBV reactivation (P < 0.05).To study the impact of preoperative anti-viral therapy on postoperative HBV reactivation:-the incidence of HBV reactivation was higher in the control group than in the combined group (19.7% vs.6.6%,P < 0.05).In the combined group,there was no significant difference between patients who received anti-viral therapy and those who were treatment-naive (5.3% vs.7.1%,P >0.05).In the control group,a higher incidence of HBV reactivation was found in patients with treatment-na(i)ve than in patients who received anti-viral therapy (26.1 % vs.0,P < 0.05).For the patients who received anti-viral therapy,there was no significant difference between the combined group and the control group (5.3% vs.0,P > 0.05).In patients with treatment-na(i)ve,a higher incidence of HBV reactivation was observed in the control group than the combined group (26.1% vs.7.1%,P < 0.05).Conclusions In patients who were not treated with antiviral therapy,hepatectomy combined with splenectomy decreased the incidence of postoperative HBV reactivation in patient with HCC ≤5 cm and with hypersplenism.For the patients who received preoperative anti-viral therapy,the incidence of postoperative HBV reactivation was not decreased with hepatectomy combined with splenectomy.
6.Hepatectomy combined with splenectomy in patients with hepatocellular carcinoma with Barcelona Clinic Liver Cancer Stage A and portal hypertension
Jiaobang XU ; Qiaoyun LIU ; Guozheng PAN ; Xichao WANG ; Jian ZHANG ; Rui ZHU ; Qingzhong YUAN
Chinese Journal of Hepatobiliary Surgery 2017;23(6):365-369
Objective To evaluate the peri-operative and survival outcomes of hepatectomy combined with splenectomy in patients with hepatocellular carcinoma with Barcelona Clinic Liver Cancer Stage A and portal hypertension.Methods We retrospectively analyzed the data on patients with hepatocellular carcinoma with Barcelona Clinic Liver Cancer Stage A and portal hypertension who underwent surgery at the Shengli Oilfield Central Hospital between July 2008 and June 2015.According to the operative method,the patients were classified as the experimental group (hepatectomy combined with splenectomy) and the control group (hepatectomy).We compared and analyzed the clinical data between these two groups,which included the operation time,blood loss,duration of hepatic portal occlusion,width of surgical resection margin,liver function,PLT,HBV reactivation,time to remove drainage tube,complications,upper gastrointestinal hemorrhage rate and survival outcomes.Results (1) The operation time,blood loss,PLT at 1 week and 1 month after surgery in the experimental group were all significantly higher than the control group [(161.4 ± 38.3) min vs.(119.2±36.4) min,(268.7±72.1) vs.(201.3±61.3) ml,(189.2±51.3) ×109/L vs.(81.9±32.2) ×109/L,(327.4±69.1) ×109/L vs.(84.5±28.5) × 109/L (all P<0.05),respectively].The time to remove drainage tube,duration of hepatic portal occlusion,width of resection surgical margin,TBil,complications and upper gastrointestinal hemorrhage rates of the two groups were not significantly different (all P > 0.05).The HBV reactivation rate,ALT and AST in the experimental group were significantly lower than the control group [3.9% (2/51) vs.18.2% (12/66),(45.7 ± 11.4) U/L vs.(58.3±14.7) U/L,(48.1±12.4) U/Lvs.(61.3±15.1) U/L (allP<0.05),respectively].(2) The 1,3 and 5-year recurrence free survival rates were not significantly different between the experimental and control groups [84.3 %,34.1%,27.3 % vs.78.8 %,42.1%,9.7 % (all P > 0.05),respectively].The 1,3 and 5-year overall survival rates in the experimental Group were significantly higher than the control group [94.1%,66.3 %,33.5 % vs.90.9%,46.7%,16.1% (all P < 0.05),respectively].Conclusion Combined liver and spleen resection was a safe and efficacious modality to treat patients with BCLC A hepatocellular carcinoma,which reduced the incidence of HBV reactivation and improved the overall survival.